Joseph Fralin Woody
CIK: 0001709989
Joseph Fralin Woody's purchase track record
Joseph Fralin Woody has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/9/2026 | RCEL | $63K | +152.7% | pending | — |
| 6/1/2026 | RCEL | $126K | +129.9% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RCEL | ▲ Buy | Open Market | 5,200 | $21K | 6/9/2026 | View on chart |
| RCEL | ▲ Buy | Open Market | 5,000 | $21K | 6/9/2026 | View on chart |
| RCEL | ▲ Buy | Open Market | 5,000 | $21K | 6/9/2026 | View on chart |
| RCEL | ▲ Buy | Open Market | 5,000 | $20K | 6/3/2026 | View on chart |
| RCEL | ▲ Buy | Open Market | 5,000 | $20K | 6/3/2026 | View on chart |
| RCEL | ▲ Buy | Open Market | 5,000 | $21K | 6/2/2026 | View on chart |
| RCEL | ▲ Buy | Open Market | 5,000 | $21K | 6/2/2026 | View on chart |
| RCEL | ▲ Buy | Open Market | 5,000 | $22K | 6/1/2026 | View on chart |
| RCEL | ▲ Buy | Open Market | 5,000 | $21K | 6/1/2026 | View on chart |
| RCEL | ▲ Buy | Grant | 22,214 | — | 1/20/2026 | View on chart |
| RCEL | ▲ Buy | Grant | 40,547 | — | 1/5/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat
PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat. PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.